GlassScriptPhysician profile
Alex Mcdonald
NPI 1710470174
$5,049.01
in general payments reported to CMS, 2019-2025
28 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.45 · 2022: $1,996 · 2023: $1,900 · 2024: $681 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,956 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.43 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,276.43 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,090.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $496.91 | 2022-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $409.81 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Paratek Pharmaceuticals, INC. | $244.74 | 2024 | Nuzyra |
| Pfizer INC. | $229.21 | 2022-2024 | |
| Glaxosmithkline, LLC. | $227.09 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $183.91 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $166.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.53 | 2022-2023 | Xifaxan |
| Dexcom, INC. | $84.38 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $82.27 | 2022-2023 | Trintellix |
| Abbott Laboratories | $64.94 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $38.31 | 2023 | Nexletol, Contrave |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.49 | 2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $33.43 | 2022-2023 | Belsomra |
| Kedrion Biopharma, INC. | $22.63 | 2023 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Horizon Therapeutics Plc | $22.61 | 2023 | Krystexxa |
| Boston Scientific Corporation | $20.35 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.80 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.59 | 2021 | |
| Genentech USA, INC. | $17.50 | 2021 | |
| Sumitomo Pharma America, INC. | $17.02 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $15.00 | 2023 | |
| Shield Therapeutics INC | $14.38 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.